FLT3

FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).

MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.

MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.

MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.

PROTAC FLT-3 degrader 1 is a von Hippel-Lindau-based PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction.

FLT3-IN-16 is a potent FLT3 inhibitor with an IC50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia.

AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC50=1μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML).

Tuspetinib (HM43239) is a selective FLT3 inhibitor with oral activity, with IC50 values of 1.1 nM (wild-type FLT3), 1.8 nM (FLT3 ITD mutation), and 1.0 nM (FLT3 D835Y mutation). As a reversible type I inhibitor, Tuspetinib directly inhibits the kinase activity of FLT3 and regulates p-STAT5, p-ERK SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation of leukemia cells and induces apoptosis.

HPK1-IN-2 didrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity.

PF15 TFA is a PROTAC connected by ligands for FLT3 kinase and CRBN.

FLT3-IN-17 inhibits CYPs and FLT3 mutants activity (IC50s: <0.5 nM for D835Y).

AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM).

RSH-7 is a potent BTK and FLT3 inhibitor with IC50s of 47, 12 nM, respectively.

FLT3-IN-19 (Comp 50) is a potent and selective FLT3 inhibitor with IC50 of 0.213 nM.

PHI-101 is an orally active FLT3 inhibitor that overcomes resistance to multiple drug-resistant mutations.

Wu-5 is a USP10 inhibitor that can inhibit FLT3 and AMPK pathways, induce FLT3-ITD degradation and induce apoptosis.

CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively.

IRAK1/4/pan-FLT3 Kinase-IN-1 hydrochloride is an orally active, potent and selective IRAK / pan-FLT3 kinase inhibitor with IC 50 s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively.

HPK1-IN-2 TFA is an orally active HPK1 inhibitor ( IC 50 < 0.05 µM) with antitumor activity.

Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib.

VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold.

Tandutinib (MLN518) (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib (MLN518) can be used for acute myelogenous leukemia (AML). Tandutinib (MLN518) has the ability to cross the blood-brain barrier.